This test looks for two specific genetic variants linked to hereditary thrombophilia, one in the F5 gene called Factor V Leiden, and one in the F2 gene called Prothrombin G20210A. People with the genetic variants included in this test are more likely to develop harmful blood clots.

Our Traits Reports explore how your DNA influences your appearance and senses, from eye color to taste preferences. These reports can tell you about your genetics and other factors that make you more or less likely to have different traits. They're a fun way to learn more about your genetics and how 23andMe works.

After you provide a saliva sample, 23andMe uses genotyping to analyze your DNA. This means we look at specific locations in your genome that are known to differ between people. We then turn those results into personalized genetic reports on everything from ancestry composition to traits to genetic health risks.

Our precision values for the vast majority of populations are greater than 90%, indicating high accuracy, meaning when we are confident in our ability to predict a piece of DNA as coming from one of our reference populations.

Genetic variants in Leiden factor coding gene (F5) and in prothrombin gene (F2) cause inherited thrombophilia which is associated with increased risk of intravascular thrombosis, thromboembolism and cerebral stroke.

Factor V Leiden thrombophilia is an inherited disorder of blood clotting . Factor V Leiden is the name of a specific gene mutation that results in thrombophilia, which is an increased tendency to form abnormal blood clots that can block blood vessels.

23andMe states their analytical validity is greater than 99% accurate for health data, notes Klee. “This means that when they are doing the genetic testing, there is a greater than 99% chance that they accurately tell which DNA base pair is present at the genetic marker they are testing,” she explains.

23andMe uses genotyping, not sequencing, to analyze your DNA. Sequencing technology has not yet progressed to the point where it is feasible to sequence an entire person's genome quickly and cheaply enough to keep costs down for consumers.

Currently, there are over 2000+ Country Matches and Genetic Groups in the Ancestry Composition Report. The global populations available in Ancestry Composition are: European. Central & South Asian.

23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent.

Based on a meta-analysis, the F5 mutation is associated with an increased risk of Budd-Chiari syndrome, portal vein thrombosis without cirrhosis, and portal vein thrombosis in cirrhosis. Found a novel gain-of-function mutation in the F5 gene (c.

Overview. Factor V Leiden (FAK-tur five LIDE-n) is a mutation of one of the clotting factors in the blood. This mutation can increase your chance of developing abnormal blood clots, most commonly in your legs or lungs. Most people with factor V Leiden never develop abnormal clots.